VarmX’s lead compound VMX-C001 is intended to safely and effectively restore hemostasis in case of bleeding or emergency surgery in patients taking so-called oral factor Xa inhibitors.
Synthetic oral factor Xa inhibitors (such as edoxaban, rivaroxaban and apixaban) belong to the latest generation of anticoagulants and their world-wide use by patients at risk of thrombosis and stroke is increasing rapidly. However, usage of factor Xa inhibitors comes at the expense of a high risk of uncontrolled and potentially life-threatening bleeding. To stop or prevent - the latter in the case of emergency surgery - these bleedings one needs a reversal agent as an antidote. Safe antidotes are not generally available at present, but VarmX has a product in its pipeline called VMX-C001 that promises safe and effective reversal.